10-12 October 2017
Boston, USA

Speakers

Expand/Collapse

Anne Parneix
VP & Senior Head of Therapeutic Area, Dermatology
Novartis

Anne Parneix earned her MD and Board Certification in Dermatology with subspecialty in Infectious Diseases from Paris University. Her in-hospital clinics focused on serious skin diseases such as Kaposi’s Sarcoma in HIV patients. As she wanted to make a greater difference for patients, she turned her attention to research. As a result, she is currently working at Novartis Pharmaceuticals Corporation, where she is a Vice President and Senior Global Program Head, leading global teams in charge of bringing new therapies to patients. Anne entered Novartis in 2003 as an Associate Director working on a new molecular entity for the treatment of Atopic Dermatitis and Psoriasis. She then joined the Global Development Organization where she held positions of increasing responsibility as Director and Executive Director on various programs in Immunology, Dermatology and Infectious Diseases. Prior to being a Senior Global Program Head, in her role of Therapeutic Area Head, she was responsible for driving clinical excellence, establishing disease area strategy, managing the internal portfolio, and supervising in-licensing activities for Dermatology. Prior to joining Novartis, Anne headed the Dermatology department of ASTER, a Contract Research Organization, in Paris for 6 years, during which she led early development studies. With her many years in health care and pharmaceutical industry, Anne has noted that her strengths lie in leadership and expertise in drug development. She is an alumna of the Novartis Executive Female Leadership Program and would like to be known as a leader in Dermatology research who brings innovative therapies to the market.

Day Two

Thursday October 12, 2017

08.30 | Panel Discussion: Pioneering Biological Therapies in Dermatology

09.45 | Beyond the Hype – Exploring the Application of Biologic Therapies to Tackle Unmet Needs in Dermatology

Braham Shroot
Dermatology Drug Development
Independent Consultant

Dr Shroot has over 35 years hands-on experience in Drug Research and Development specializing in Skin disorders including  Acne, Rosacea, Psoriasis, Atopic Dermatitis Fungal Infections, Chronic Ulcers and novel Aesthetic Biologic Products. Dr Shroot currently is an R&D  consultant to Health Care Companies, with an focus on a wide range of acute and chronic skin disorders including rare diseases.

Pre Conference Workshop

Tuesday October 10, 2017

13.00 |
Innovating Drug Delivery & Formulation of Dermatological Drugs

Burkhard Jansen
CMO
DermTech

Burkhard Jansen, MD brings a distinctive blend of dermatology medical practitioner and innovator, both national and international, to the realm of molecular dermatology. He has served as founder, director, and senior executive of a number of dermatology and oncology focused life sciences companies, primarily in the US, and also in Canada and Europe. Dr. Jansen now serves as Chief Medical Officer at DermTech, the San Diego – based world leader in non-invasive molecular dermatology. Dr. Jansen received his medical doctorate and dermatology training from the Universities of Graz and Vienna in Austria, his postdoctoral science training at the University of Minnesota, and his executive business education at UCLA. He has a background as a tenured professor of both dermatology and clinical pharmacology with FDA experience. His scientific work is published in Nature, Nature Medicine, Lancet, PNAS and a variety of dermatology and oncology journals.

Day Two

Thursday October 12, 2017

10.15 | Dermtech Adhesive Patch Biopsies For Non-Invasive Molecular Dermatology – A Novel Platform To Guide Dermatology Drug Development, Target Discovery & Microbiome Studies

Dan Piacquadio
President, CEO & CMO
Therapeutics Inc.

Dan Piacquadio, M.D. is the founder of Therapeutics Inc. and serves as its President, CEO and CMO. He started Therapeutics as a contract research organization dedicated to the field of dermatology, serving the needs of biotechnology, pharmaceutical and investment communities. His experience in clinical research, medical product development, academia and dermatology practice contribute to his exceptional insight and perspective. Dr. Piacquadio has been active in clinical research and medical product development since 1985, when he was Director of R&D for Oncotherm, a hyperthermia company, and was responsible for regulatory affairs and clinical development. He went on to lead the clinical research program for the Division of Dermatology at the University of California, San Diego and served as Director of this facility from 1989 to 1997, during which it became regarded as one of the leading academic product development groups in the United States. Dr. Piacquadio has been instrumental in the non-clinical and clinical development phases of a variety of soft tissue augmentation products including Hylaform (Biomatrix) and played a key role in defining regulatory strategy and clinical development of the first laser-based hair removal technology pioneered by Thermolase. As a Consultant to the FDA Generic Drug Group, he co-led the development of the current bioequivalency standards for topical steroids. Dr. Piacquadio holds a Bachelor of Science degree in Biomedical Engineering from Rensselaer Polytechnic Institute and his Medical degree from the University of Pennsylvania. He received his graduate clinical training at Brown University as an intern in Internal Medicine and his Dermatology training at the University of California, San Diego.

Day Two

Thursday October 12, 2017

11.30 | Clinical Development: Pathways to Success or Failure

David Giljohann
CEO
Exicure

Dr. Giljohann has served as Exicure’s Chief Executive Officer since November 2013 and been on its board of directors since March 2014. From July 2012 to October 2013, Dr. Giljohann was Exicure’s Chief Operating Officer and its founding scientist in 2011. From 2011 to June 2012, Dr. Giljohann served as the company’s principal scientist. Prior to that, Dr. Giljohann was the founding scientist of AuraSense, LLC in 2009. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare™, and spherical nucleic acid constructs. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. He was also named to the Analytical Scientist's "Top 40 Under 40 Power List" in 2014. Dr. Giljohann has contributed to over 25 manuscripts and over 100 patents and applications. Dr. Giljohann obtained his Ph.D. in 2009 from Northwestern University.

Day One

Wednesday October 11, 2017

14.45 | Targeting Diseases Using Topical Treatments with Spherical Nucleic Acids

09.00 | Opening Keynote Panel Discussion: A Therapeutic Revolution in Dermatology – Bridging the Gaps & Opportunities

Dogan Fidan
Head of Global Strategic Franchise, Immunology & Inflammation
Galderma

Dogan Fidan is currently the Head of Global Strategic Franchise at Galderma. He has over 20 years of experience in pharma, public agencies & academia. Prior to joining Galderma, he spent 13 years in Sanofi holding senior corporate roles in commercial, health economics, and medical affairs organizations. He also spent four years at NICE in the UK, where he acted as a technical lead in health technology appraisals. He is a Doctor of Medicine (MD), has a PhD in Public Health, MSc in Health Economics, and MBA.

Day Two

Thursday October 12, 2017

16.45 | Panel Discussion: Addressing the Overall Concern of Rising Treatment Costs in Dermatology

16.15 | How to Win in the Competitive Market Place?

Ernst Kriehuber
Director Translational Medicine, Dermatology & Immune Mediated Diseases
Novartis Institutes for Biomedical Research

Ernst Kriehuber received his MD degree from Medical University Vienna. He worked with Peter Elias (UCSF) on the permeability barrier of the skin and with Georg Stingl (Medical University Vienna) and Giulio Superti-Furga (CeMM) on immunemechanisms in skin inflammation. Ernst joined Novartis in 2010 and held different positions in discovery and translational research. Among others, Ernst has led a Novartis Institutes for BioMedical Research site dedicated to dermatologic drug discovery in Vienna, Austria, before joining the companies’ headquarters in Basel, Switzerland. In Basel, Ernst has so far has contributed to strategic outlines of NIBR’s dermatology and respiratory TA and DA strategies and was part of leadership teams and decision boards.  In addition, Ernst was leading teams of translational and computational biologists to explore novel indications and druggable nodes in dermatology and other therapeutic areas. Currently Ernst holds responsibilities for the preclinical dermatology portfolio and business development activities for dermatology.

Day One

Wednesday October 11, 2017

11.45 | Translational Research in Dermatology – Setting the Course for Successful/Accelerated Clinical Development

Day Two

Thursday October 12, 2017

08.30 | Panel Discussion: Pioneering Biological Therapies in Dermatology

Frank Nestle
Head of Immunology & Inflammation Therapeutic Research Area & CSO North America
Sanofi US

Dr. Frank Nestle is Global Head of Immunology & Inflammation Research Therapeutic Area and also North America Chief Scientific Officer at Sanofi based in Cambridge, Massachusetts. As Therapeutic Area Head, he leads research and development efforts to build a robust and innovative portfolio in immunology and inflammation, helping to achieve a leadership position in critical areas such as chronic inflammatory and autoimmune disease He previously worked at King’s College London (United Kingdom), where he keeps a professorial affiliation. At King’s, Frank led research and early development projects and teams in the area of Dermatology and Immunology. In addition, he held a number of executive and non-executive roles in hospitals and academia within the UK, in particular at the Biomedical Research Center. There, he built the Clinical Research Facilities and led the Biomarker and Co-Diagnostics Cluster overseeing ross-disease area precision medicine projects and the translational research platforms including Genomics, Flow Cytometry, Translational Bioinformatics and Bioresource. Frank is the outgoing President of the Federation of Clinical Immunology Societies (FOCIS), and also a Fellow of the Academy of Medical Sciences and a Senior Investigator Emeritus at the National Institute for Health Research (NIHR). He has authored over 200 scientific articles and has received several awards and honors, including the Alfred Marchionini Research Award at the 20th World Congress of Dermatology.

Day Two

Thursday October 12, 2017

08.30 | Panel Discussion: Pioneering Biological Therapies in Dermatology

09.15 | Advancing Dermatology Therapies with Biologics

Gavin Corcoran
CMO
Allergan

Gavin Corcoran, MD FACP is the Chief Medical Officer at Allergan, plc.  Dr Corcoran is a native of South Africa where he received his medical degree at the University of the Witwatersrand.  He subsequently completed his Internal Medicine and Infectious Diseases training at the University of Texas Health Sciences Center in San Antonio, Tx.  After practicing in private practice and academics he joined the pharmaceutical industry.  He has worked at a number of companies – both medium and large – and spent time in Clinical Development, Regulatory Affairs and some time running a whole R&D organization.  In his current position, Dr Corcoran is responsible for worldwide Medical Affairs, HEOR and Safety.  His focus in this position is to work with his team and the rest of the organization to ensure a patient centric approach to new product development as well and a focus on access.

Day Two

Thursday October 12, 2017

16.45 | Panel Discussion: Addressing the Overall Concern of Rising Treatment Costs in Dermatology

15.00 | Panel Discussion: Dermatology Drug Development – A Regulatory Paradigm Shift

Geoffrey Hird
Executive Director of Pharmaceutics and CMC
Liquidia

Geoff Hird has over 15 years of pharmaceutical industry experience in product development of topical, parenteral, pulmonary and oral formulations of small and large molecules. He is currently focused on integrating Liquidia’s PRINT® technology into topical formulations being developed with partners. Prior to joining Liquidia, Geoff led global CMC teams developing topical drugs at GSK and Eisai.  In addition to working in industry, Geoff enjoys teaching as an Adjunct Professor at the UNC Chapel Hill Eschelmen School of Pharmacy and reviewing grants for the American Cancer Society as a member of the Cancer Drug Discovery Study Section. Geoff received his Ph.D. in Chemistry from Duke University where he developed a novel liposomal drug delivery system.

Day One

Wednesday October 11, 2017

16.25 | Panel Discussion: Debating the Therapeutic Developments in Topicals

Greg P. Licholai
President & CSO
Castle Creek Pharmaceuticals

Greg is President and Chief Scientific Officer at Castle Creek Pharmaceuticals. He is a member of the Executive Leadership Team and is responsible for all research and development activities, technical operations, medical affairs and the company’s scientific, regulatory, medical and clinical strategies. Greg is on faculty at the Yale School of Management, teaches the capstone lectures on Sustainable Innovation in Healthcare, and has written multiple articles on biopharmaceutical innovation. Previously he was founder and President of Elpidera Therapeutics, a Moderna Therapeutics venture portfolio company focused on developing messenger RNA therapies for rare genetic and metabolic diseases. He was a partner-level consultant at McKinsey & Company, and Senior Vice President for Real World and Late Stage Research at Quintiles, Inc. He was Chief Operating Officer at Proteostasis, focused on rare disease. He was one of the original employees at Amicus Therapeutics, focused on pharmacological chaperones for rare diseases. He was also co-founder of Immunome, a biotechnology firm with a proprietary antibody platform for oncology. He was a venture capitalist at Domain Associates. He was director of Ventures and Business Development at Medtronic Neurological. Greg attended Columbia University and Boston College, received an M.D. from Yale Medical School and M.B.A from Harvard Business School. He trained at the Brigham and Women’s, Children’s, and Massachusetts General Hospitals. He was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health. He performed research in molecular genetics at Yale University. He worked in molecular oncology at Rockefeller University. He is on the advisory board of the National Tay Sachs and Allied Disease Foundation, the Partnership for Palliative Care, and Yale Health Conference.

Day Two

Thursday October 12, 2017

16.45 | Panel Discussion: Addressing the Overall Concern of Rising Treatment Costs in Dermatology

12.00 | New Horizons in Dermatology – Rare & Orphan Disease Drug Development Opportunities & Challenges

Jean-Philippe (JP) Therrien
VP, Skin Biology
EnDev Laboratories™

JP joined EnDev in November 2016 having held positions of increasing responsibility as Director of Skin Biology with the Dermatology Therapeutic Area at GlaxoSmithKline (GSK), previously Stiefel, a GSK company and Stiefel. Prior to joining Stiefel/GSK, JP spent 6 years at the National Cancer Institute/National Institute of Health on the Dermatology Branch as Post-Doctoral and Research fellow working on human skin gene therapy. JP received a B.S. in Biochemistry from University of Sherbrooke (Quebec, Canada) and Ph.D. in Molecular & Cellular Biology/Photobiology from Laval University (Quebec, Canada). JP brings more than 20 years of experience in dermatological research and more than 8 years of experience in topical product development for both, prescription (Rx) and consumer healthcare/cosmetic (Cx) products, where his work has been extensively published in high-impact journals, scientific presentations, patent applications, and sale aids. JP is also a member of the Board of Directors of the Society of Investigative Dermatology.

Day One

Wednesday October 11, 2017

12.15 | Skin Biology - A Valuable Tool for the Innovation & Development of Novel Therapeutic Alternatives in Dermatology

Jeremy Drummond
VP, Business Development
MedPharm

Jeremy Drummond, PhD, MRSC is the Vice President Business Development for MedPharm. MedPharm is well established as the global leader in topical and transdermal product design, development, and manufacturing services to the pharmaceutical industry. In this role, he helps clients understand how MedPharm can mitigate risk and shorten their development timelines for their generic or proprietary pharmaceutical products. He leverages his scientific background and industry experience to ensure clients can tap into MedPharm’s innovative solutions for the skin, nail, mucosal membrane, ophthalmic, and airways which are recognised for their scientific rigour by regulators and investors alike.  He has a Biochemistry BSc from the University of Sussex and a PhD in organic chemistry from the University of Cambridge. He started his career as a formulation scientist at major multinationals and has spent over 20 years in roles of increasing responsibility leading the commercial supply of product and services to the pharmaceutical companies across the globe.

Day One

Wednesday October 11, 2017

15.15 | Innovations to Mitigate Risk in Topical Formulation Development

Kim Domela Kjøeller
Executive VP, Global R&D
LEO Pharma A/S

After Graduating from the Copenhagen Medical Faculty in 1994, Kim Kjøller, held several positions at Copenhagen University Hospitals in medicine and surgery until joining the Danish Cancer Society, Institute for Epidemiologic Cancer Research in 1996. Kim Kjøller joined the Pharmaceutical industry as Medical Manager in Synthelabo 1999 and has since held various positions across R&D, Strategic Marketing and General Management at Sanofi, Lundbeck, Sanofi Pasteur MSD and LEO Pharma from 2010. Kim Kjøller is author/Co-Author of 35+ scientific publications, and has given lectures at Scientific Meetings in Denmark and the Nordics as well as at Pharma Industry Meetings in Europe and the US.

Day One

Wednesday October 11, 2017

09.45 | Precision Medicine in Dermatology - Revolutionizing R&D & Providing Optimal Treatment for Patients

09.00 | Opening Keynote Panel Discussion: A Therapeutic Revolution in Dermatology – Bridging the Gaps & Opportunities

Krishna Menon
President & CSO
Innovation Pharmaceuticals Inc.

Dr. Menon is a co-founder of Innovation Pharmaceuticals, Inc, serving as Chief Scientific Officer, and Board Member. He is a leading pharmaceutical scientist with over 30 years of drug development experience in academia and industry. Prior to Cellceutix, Dr. Menon served at Eli Lilly as Group Leader, Cancer In Vivo Research and Clinical Development. While there, Dr. Menon played an integral role in lead selection and pre-clinical development of Gemzar and Alimta, two blockbuster oncology drugs. He was awarded Eli Lilly’s prestigious President’s Recognition Award. Earlier in his professional career, he held research scientist positions at Miles(Bayer) Laboratories and Dana Farber Cancer Research Institute. Dr. Menon is a trained veterinary surgeon (VMD) and holds a PhD (Pharmacology) from Kerala University.

Day One

Wednesday October 11, 2017

15.55 | Innovation in Oral Immunomodulators for the Treatment of Psoriasis & Other Dermatological Conditions

Marc Brown
Co-Founder & CSO
MedPharm

Professor Marc Brown received his BSc(Hons) and PhD in Pharmaceutical Chemistry from Loughborough University. In 2006, after 14 years working as an academic at King’s College London (KCL) he took up a position as Chair of Pharmaceutics in the School of Pharmacy, University of Hertfordshire and has been subsequently awarded Honorary Professorial positions at the School of Pharmacy, University of Reading and the Institute of Pharmaceutical Sciences, King’s College London. His research interests lie mainly in drug delivery to the skin, nail and mucosal membranes and he has over 200 publications and 25 inventions describing his work. In 1998 whilst at KCL,  Professor Brown co-founded MedPharm Ltd,  a contract research organisation specialising in the development of topical and transdermal medicines. He acts as Chief Scientific Officer of MedPharm which employs ca. 140 people in its GMP/GLP accredited facilities in the UK and the US. Prof Brown has been involved in the development of 38 topical and transdermal medicines and devices that have gained regulatory approval around the world. These include two generic topical products that were approved in the EU based on MedPharm’s validated in vitro and ex vivo performance testing models.

Pre Conference Workshop

Tuesday October 10, 2017

13.00 |
Innovating Drug Delivery & Formulation of Dermatological Drugs

Marie Bernasconi
Senior Director & Head of Dermatology Therapeutic Area R&D
Almirall

Marie Bernasconi has over than 20 years of experience in drug development (prescription and OTC) and project management in pharmaceutical industry, covering all aspects of drug development, ranging from idea generation, NEC research, early proof-of-concept studies to global registration and commercialization. She led products (small molecules or biologics) to successful registrations and launches, some of which were major contributors in the growth of the in various disease areas as immunology/inflammation/ immunosuppression. Currently, she lead the Dermatology Therapeutic Area R&D including aesthetics at Almirall, in charge of project strategy from idea generation, through all stages of development: She is the head of skin pharmacology, clinical development and clinical operations departments.

Day Two

Thursday October 12, 2017

15.00 | Panel Discussion: Dermatology Drug Development – A Regulatory Paradigm Shift

11.00 | Psoriasis: The Shift in Treatment Paradigm in the Last 25 Years

Mayte Suarez-Farinas
Associate Professor
Biostatistics Icahn School of Medicine at Mount Sinai

Dr Suarez-Farinas is an Associate Professor of Biostatistics at the Icahn School of Medicine at Mount Sinai (IMMS). Her research interests focus in developing robust statistical techniques to integrate complex high-throughput data, tailored to immune-related skin disease. She has worked extensively in characterizing psoriasis and eczema endotypes and in mechanistic clinical trials in those diseases, where immune-directed therapeutics are combined with large-scale molecular studies, to elucidate the molecular pathways that cause pathogenic inflammation and regulate normal human immune responses. More recently she has develop precision medicine algorithms to measure treatment response in a short term, proof of concept clinical trial.

Day Two

Thursday October 12, 2017

13.30 | Can Molecular & Machine Learning Bring Efficiency to Clinical Trials in Dermatology?

Monica Luchi
former CMO & Executive VP
Immune Pharmaceuticals

Dr. Monica E. Luchi is the President and Chief Medical Officer for Immune Pharmaceuticals. She is a Board-certified rheumatologist with over 17 years of industry experience, at both large pharmaceutical and small biotech companies.  Prior to joining Immune, Dr. Luchi held senior positions at Novartis, Incyte and Mesoblast, where she led cross-functional teams and drove strategy across all phases of clinical development in a variety of therapeutic areas including inflammation, dermatology, oncology and immunology. In addition, Dr. Luchi has been instrumental in driving business interests of the biotech companies where she worked in order to engage development partners and to strengthen financial assets which supported further progress of the companies’ development activities. She is adjunct Clinical Assistant Professor on faculty at the University of Pennsylvania where she completed her fellowship, and continues active patient care one half day per week. She has recently served on the Metro chapter board for the Healthcare Businesswoman’s Association. Dr. Luchi obtained undergraduate degrees in Biology and in Health Science Policy at the University of Maryland, Baltimore Co. Campus. She received her MD from Northeastern Ohio Universities, College of Medicine, and an MBA with a concentration in healthcare from George Washington University.

Day One

Wednesday October 11, 2017

17.10 | Chairman’s Closing Remarks

08.45 | Chairman’s Opening Remarks

Day Two

Thursday October 12, 2017

17.30 | Chairman’s Closing Remarks

14.00 | Challenges with Dermatology Clinical Study Endpoints

08.20 | Chairman’s Opening Remarks

Paul F. Lizzul
CMO
Sienna Biopharmaceuticals

Paul F. Lizzul, M.D., Ph.D., M.P.H., M.B.A. is Chief Medical Officer of Sienna Biopharmaceuticals.  Sienna is clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics.  Our objective is to progress a multi-asset pipeline of safe and effective topical therapies that enhance the health, appearance and quality of life of dermatology patients.

Day One

Wednesday October 11, 2017

13.45 | Addressing the Innovation Gap in Topical Dermatology Drug Development

09.00 | Opening Keynote Panel Discussion: A Therapeutic Revolution in Dermatology – Bridging the Gaps & Opportunities

Sujatha Sonti
VP, Topical Product Development
GlaxoSmithKline

Sujatha is a pharmacist by training and received her Ph. D. in Pharmaceutical Sciences. Her graduate research focused mainly on the delivery of large molecules: antisense oligonucleotides and gene therapy for the treatment of lung inflammation. Her industrial career started in the department of Cell Biology and In Vitro Toxicology at Avon Products, Inc and since then she has taken on several roles of increasing responsibilities in topical product development at Ionis Pharmaceuticals, SkinMedica, Inc (a division of Allergan) and Medicis Pharmaceuticals. Sujatha joined the Stiefel division of GSK in 2014 and currently heads the Topical Product Development group within the Dermatology Unit at GSK. She has over 15 years of dermatology product development experience (prescription and consumer products) and has had the incredible opportunity of commercially launching several topical prescription products and over 35 Cosmetic/OTC products. Sujatha was recently recognized as a GSK Senior Fellow. She was awarded the 2016 Rising Star by HBA (Healthcare Business Association) as a women leader who has made significant contributions in her area of expertise.

Day One

Wednesday October 11, 2017

16.25 | Panel Discussion: Debating the Therapeutic Developments in Topicals

14.15 | Key considerations in designing topical formulations

Tomoko Maeda-Chubachi
VP, Medical Dermatology
Novan, Inc.

Tomoko Maeda-Chubachi is a dermatologist by training and seasoned drug developer. She has spent most recent years dedicated to dermatology: psoriasis, atopic dermatitis, pemphigus, androgenic alopecia, etc. She has an extensive experience in all aspects of clinical activities to manage first-in-human (FIH), phase 1, phase 2 to 3 trials, including pediatric clinical trials. She also led end of phase 2 (EOP2) meetings, regulatory submissions for US (FDA), Europe (EMA), Japan (PMDA) and emerging markets from clinical perspective. She has also been involved in various Medical Affairs activities.

Day One

Wednesday October 11, 2017

16.25 | Panel Discussion: Debating the Therapeutic Developments in Topicals

Day Two

Thursday October 12, 2017

14.30 | Collaborative Efforts to Harmonize the Endpoints & Outcome Measures in Dermatological Diseases

Vijendra Nalamothu
CEO & Co-Founder
Tergus Pharma

Dr. Vijendra Nalamothu is CEO and Co-Founder of Tergus Pharma, the industry leader in topical formulation and development services, analysis, testing and cGMP clinical supply manufacturing. Dr. Nalamothu has been a leader in topical pharmaceutical development for more than two decades and holds several patents. His efforts have led to a number of successful commercial products. His passion is to develop products that speak for themselves. After earning his PhD in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy, he worked at Sanofi-aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He has also served as Global Head of Dermatology R&D at Promius Pharma, a wholly-owned subsidiary of Dr. Reddy’s Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization. Dr. Nalamothu’s interests include novel dosage form design and development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles and accolades. He is a sought-after speaker at conferences worldwide.

Day One

Wednesday October 11, 2017

09.00 | Opening Keynote Panel Discussion: A Therapeutic Revolution in Dermatology – Bridging the Gaps & Opportunities